Research programme: macular degeneration therapy - Geron
Alternative Names: Macular degeneration therapy research programme - GeronLatest Information Update: 18 Nov 2011
At a glance
- Originator Geron Corporation
- Class
- Mechanism of Action Telomerase activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Macular degeneration
Most Recent Events
- 31 Dec 2006 Development discontinued for Macular degeneration before 2006
- 14 Jun 2005 No development reported - Preclinical for Macular degeneration in USA (unspecified route)
- 14 Jun 2001 New profile